It is with deep sadness that we announce the passing of Joseph Wilson, who passed away peacefully on December 29th, 2024 at the age of 67. Joe was born February 7, 1957, he grew up in Zanesville ...

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

The Cultural Institute of Radical Contemporary Arts (CIRCA) today unveils the 30 shortlisted artists for the CIRCA PRIZE 2023 — an initiative that invests in the future of art and culture by awarding ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring for people living with heart failure. Called Digitiva, it combines Eko ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas has become the first drugmaker to bring a drug in the neurokinin 3 (NK3) receptor antagonist class to the US market, after getting FDA approval of fezolinetant for a common and ...

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector, The $40-per-share offer values ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Astellas reported sales of around $22 million for Xospata in the first quarter of fiscal 2019, and has said it expects that to increase to around $140m for the full-year. George Underwood 28 ...